Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 1
1998 1
2002 1
2005 1
2006 1
2007 5
2008 1
2009 3
2010 7
2011 4
2012 6
2013 5
2014 9
2015 16
2016 17
2017 16
2018 26
2019 32
2020 35
2021 40
2022 39
2023 44
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Motzer RJ, Russo P, Grünwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barthélémy P, Goh JC, Ye D, Lingua A, Lattouf JB, Albigès L, George S, Shuch B, Sosman J, Staehler M, Vázquez Estévez S, Simsek B, Spiridigliozzi J, Chudnovsky A, Bex A. Motzer RJ, et al. Among authors: buti s. Lancet. 2023 Mar 11;401(10379):821-832. doi: 10.1016/S0140-6736(22)02574-0. Epub 2023 Feb 9. Lancet. 2023. PMID: 36774933 Free PMC article. Clinical Trial.
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
Cortellini A, D'Alessio A, Cleary S, Buti S, Bersanelli M, Bordi P, Tonini G, Vincenzi B, Tucci M, Russo A, Pantano F, Russano M, Stucci LS, Sergi MC, Falconi M, Zarzana MA, Santini D, Spagnolo F, Tanda ET, Rastelli F, Giorgi FC, Pergolesi F, Giusti R, Filetti M, Lo Bianco F, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Queirolo P, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Spoto C, Vitale MG, Cannita K, Gennari A, Morganstein DL, Mallardo D, Nibid L, Sabarese G, Brunetti L, Perrone G, Ascierto PA, Ficorella C, Pinato DJ. Cortellini A, et al. Among authors: buti s. Clin Cancer Res. 2023 Jul 14;29(14):2714-2724. doi: 10.1158/1078-0432.CCR-22-3116. Clin Cancer Res. 2023. PMID: 37125965
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Ramaiya N, Presley CJ, Owen DH, Abou Alaiwi S, Nassar A, Ricciuti B, Lamberti G, Bersanelli M, Casartelli C, Buti S, Marchetti P, Giusti R, Filetti M, Vanella V, Mallardo D, Macherla S, Sussman TA, Botticelli A, Galetta D, Catino A, Pizzutilo P, Genova C, Dal Bello MG, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Choueiri TK, Johnson DB, Marron TU, Wang Y, Naqash AR. Nebhan CA, et al. Among authors: buti s. JAMA Oncol. 2021 Dec 1;7(12):1856-1861. doi: 10.1001/jamaoncol.2021.4960. JAMA Oncol. 2021. PMID: 34734989 Free PMC article.
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives.
Rebuzzi SE, Rescigno P, Catalano F, Mollica V, Vogl UM, Marandino L, Massari F, Pereira Mestre R, Zanardi E, Signori A, Buti S, Bauckneht M, Gillessen S, Banna GL, Fornarini G. Rebuzzi SE, et al. Among authors: buti s. Cancers (Basel). 2022 Feb 28;14(5):1245. doi: 10.3390/cancers14051245. Cancers (Basel). 2022. PMID: 35267553 Free PMC article. Review.
The bHLH network underlying plant shade-avoidance.
Buti S, Hayes S, Pierik R. Buti S, et al. Physiol Plant. 2020 Jul;169(3):312-324. doi: 10.1111/ppl.13074. Epub 2020 Feb 28. Physiol Plant. 2020. PMID: 32053251 Free PMC article. Review.
Reassessing Human Adipose Tissue.
Buti S, Cortellini A, Bersanelli M. Buti S, et al. N Engl J Med. 2022 Jun 2;386(22):e61. doi: 10.1056/NEJMc2204077. N Engl J Med. 2022. PMID: 35648727 No abstract available.
Drug-Induced Megaloblastic Anemia.
Buti S, Sikokis A. Buti S, et al. N Engl J Med. 2016 Feb 18;374(7):695-6. doi: 10.1056/NEJMc1515180. N Engl J Med. 2016. PMID: 26886542 No abstract available.
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
Messina C, Giunta EF, Signori A, Rebuzzi SE, Banna GL, Maniam A, Buti S, Cattrini C, Fornarini G, Bauckneht M, Greystoke A, Plummer R, Oing C, Rescigno P. Messina C, et al. Among authors: buti s. Eur Urol Oncol. 2023 Aug 11:S2588-9311(23)00155-4. doi: 10.1016/j.euo.2023.07.013. Online ahead of print. Eur Urol Oncol. 2023. PMID: 37574390 Free article. Review.
Pembrolizumab plus enfortumab vedotin in urothelial cancer.
Santoni M, Takeshita H, Massari F, Bamias A, Cerbone L, Fiala O, Mollica V, Buti S, Santoni A, Bellmunt J. Santoni M, et al. Among authors: buti s. Nat Rev Urol. 2024 Jan 24. doi: 10.1038/s41585-024-00858-y. Online ahead of print. Nat Rev Urol. 2024. PMID: 38267716 No abstract available.
AR-V7 and prostate cancer: The watershed for treatment selection?
Ciccarese C, Santoni M, Brunelli M, Buti S, Modena A, Nabissi M, Artibani W, Martignoni G, Montironi R, Tortora G, Massari F. Ciccarese C, et al. Among authors: buti s. Cancer Treat Rev. 2016 Feb;43:27-35. doi: 10.1016/j.ctrv.2015.12.003. Epub 2015 Dec 18. Cancer Treat Rev. 2016. PMID: 26827690 Review.
280 results